3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
4
Breast
4
Thoracic
2
Lymphoid
2
Gynecologic
2
CNS
2
Other solid neoplasm
1
Other hematologic neoplasm
1
Head & Neck
1
Endocrine
1
Conditions
Multiple Endocrine Neoplasia Type 1
2
Breast Neoplasms
2
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms
1
Breast Diseases
1
Interventions
Everolimus
6
Sunitinib
4
Octreotide
4
Leucovorin
4
dabrafenib
3
Fluorouracil
3
3-Iodobenzylguanidine
3
trametinib
2
selpercatinib
2
lutetium Lu 177 dotatate
2
avelumab
2
alectinib
2
PM 01183
2
Oxaliplatin
2
Irinotecan
2
Fulvestrant
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
trifluridine tipiracil drug combination
1
tipifarnib
1
telotristat ethyl
1
surufatinib
1
somapacitan
1
ribociclib
1
repotrectinib
1
pralsetinib
1
pentetreotide
1
pegfilgrastim
1
pasireotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
ribociclib
×
Endocrine
×
Clear all
NCT02422615
2023-11-30
MONALEESA-3
Novartis
Phase 3
Completed
726 enrolled
17 charts
1 FDA